We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY.
- Authors
Thieblemont, C.; Lamy, T.; Tani, M.; Krzisch, D.; Reda, G.; Tedeschi, A.; Usai, S. V.; Guarini, A.; Bijou, F.; Stathis, A.; Anastasia, A.; Devizzi, L.; Luminari, S.; Arcaini, L.; Casasnovas, O.; Gressin, R.; André, M.; Houot, R.; Bonomini, L.; Zucca, E.
- Abstract
B Introduction: b Although in a phase III trial of extranodal MZL (EMZL) patients (pts) the combination of rituximab and chlorambucil had superior progression-free and event-free survival (PFS, EFS) compared to either drug given alone (Zucca et al. JCO 2016), there is no standard front-line therapy for MZL pts requiring systemic treatment, and no randomized trial specifically addressed initial treatment for the splenic (SMZL) and nodal (NMZL) MZL subtypes.
- Subjects
RITUXIMAB; SPLENECTOMY; LYMPHOMAS; CLINICAL trials
- Publication
Hematological Oncology, 2023, Vol 41, p104
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_65